Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
1.62 ^USD	-3.57%		+20.90%	-83.49%

07-01	Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 3000E Growth Index	CI
07-01	Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2000 Growth Index	CI

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2020

January 11, 2021 at 09:16 am

Pacific Biosciences of California, Inc. provided revenue guidance for the fourth quarter ended December 31, 2020. For the quarter, the company expected revenue of approximately $27 million an estimated decrease of 3% compared with $27.9 million in the fourth quarter of 2019.

Latest news about Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 3000E Growth Index	06-30	CI
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2000 Growth Index	06-30	CI
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 3000 Growth Index	06-30	CI
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index	06-30	CI
PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry	06-27	MT
Form Bio and Pacbio Announce Collaboration to Launch New Resources Set to Transform Aav Design and Analysis Best Practices	06-27	CI
PacBio and International Research Consortium Colors Announce Release of First-Ever HiFi Long-Read Variant Database	06-10	CI
Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target	06-03	MT
Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	05-15	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	05-15	MT
Ambry Genetics and PacBio Announces Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases	05-15	CI
Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	05-13	MT
Transcript : Pacific Biosciences of California, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q1 Revenue $38.8M	05-09	MT
Pacific Biosciences of California, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	04-22	MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	04-18	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	04-18	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	04-17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	04-16	MT
Sector Update: Health Care	04-16	MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink	04-16	MT
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	04-16	CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	04-10	MT

Chart Pacific Biosciences of California, Inc.

Duration

Period

Chart Pacific Biosciences of California, Inc.

More charts

Company Profile

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-06 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pacific Biosciences of California, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.62 USD

Average target price

4.25 USD

Spread / Average Target

+162.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-83.49%	441M
THERMO FISHER SCIENTIFIC	+2.62%	208B
DANAHER CORPORATION	+6.44%	182B
INTUITIVE SURGICAL, INC.	+29.61%	155B
BOSTON SCIENTIFIC CORPORATION	+34.96%	115B
SIEMENS HEALTHINEERS AG	+3.00%	66.52B
EDWARDS LIFESCIENCES CORPORATION	+17.38%	53.93B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.26B
AGILENT TECHNOLOGIES, INC.	-5.77%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+3.71%	36.6B

Other Advanced Medical Equipment & Technology